Formulation development and evaluation of hybrid nanocarrier for cancer therapy: Taguchi orthogonal array based design.
Formulation development and evaluation of hybrid nanocarrier for cancer therapy: Taguchi orthogonal array based design.
复制标题
DOI：
10.1155/2013/712678
复制
发表时间：
2013
影响因子：
--
通讯作者：
Chougule MB
中科院分区：
文献类型：
--
作者：
Tekade RK;Chougule MB
田口正交表设计是一种统计方法，它有助于克服与耗时的全析因实验设计相关的限制。本研究采用田口正交表设计，确定了牛血清白蛋白(BSA)纳米载体(ANC)的最佳制备条件。采用L9型稳健正交表设计的田口方法对实验条件进行优化。分别在3%、4%和5%w/v、1 ： 0.75、1 ： 0.90和1 ： 1.05 v/v、40%、70%和100%v/v三个水平下，考察了牛血清白蛋白浓度(%w/v)、牛血清白蛋白溶液体积与总乙醇的比例(v/v)和稀释乙醇水溶液浓度(%v/v)三个关键影响因素。乙醇水溶液被用来提供不那么苛刻的解溶条件，并获得可控的纳米颗粒形成。相互作用图研究表明，乙醇水溶液浓度是影响纳米制剂颗粒大小的最重要参数。这种方法(牛血清白蛋白，4%w/v；牛血清白蛋白溶液与总乙醇的体积比，1 ： 0.90 v/v；稀释乙醇溶液浓度，70%v/v)能够成功地制备出载药吉西他滨(G)修饰白蛋白纳米载体(M-ANC-G)，其粒径为25.07±2.81 nm(ζ=−23.03±1.015 mV)，而常规方法制备的修饰白蛋白纳米载体(C-ANC-G)为78.01±4.99 nm(ζ=−24.88±1.37 mV)。采用壳聚糖分层法制备纳米载体C-HNC-G和M-HNC-G，粒径分别为125.29±5.62 nm(ζ=12.01±0.51 mV)和46.28±2.21 nm(ζ=15.05±0.39 mV)。考察了制剂的Zeta电位、包封率、体外释药和pH稳定性，并讨论了处方参数的影响。通过细胞毒性试验(A549和H460细胞)和细胞内化试验(H460细胞株)评价纳米制剂对生物性能的影响。
Taguchi orthogonal array design is a statistical approach that helps to overcome limitations associated with time consuming full factorial experimental design. In this study, the Taguchi orthogonal array design was applied to establish the optimum conditions for bovine serum albumin (BSA) nanocarrier (ANC) preparation. Taguchi method with L9 type of robust orthogonal array design was adopted to optimize the experimental conditions. Three key dependent factors namely, BSA concentration (% w/v), volume of BSA solution to total ethanol ratio (v : v), and concentration of diluted ethanolic aqueous solution (% v/v), were studied at three levels 3%, 4%, and 5% w/v; 1 : 0.75, 1 : 0.90, and 1 : 1.05 v/v; 40%, 70%, and 100% v/v, respectively. The ethanolic aqueous solution was used to impart less harsh condition for desolvation and attain controlled nanoparticle formation. The interaction plot studies inferred the ethanolic aqueous solution concentration to be the most influential parameter that affects the particle size of nanoformulation. This method (BSA, 4% w/v; volume of BSA solution to total ethanol ratio, 1 : 0.90 v/v; concentration of diluted ethanolic solution, 70% v/v) was able to successfully develop Gemcitabine (G) loaded modified albumin nanocarrier (M-ANC-G) of size 25.07 ± 2.81 nm (ζ = −23.03 ± 1.015 mV) as against to 78.01 ± 4.99 nm (ζ = −24.88 ± 1.37 mV) using conventional method albumin nanocarrier (C-ANC-G). Hybrid nanocarriers were generated by chitosan layering (solvent gelation technique) of respective ANC to form C-HNC-G and M-HNC-G of sizes 125.29 ± 5.62 nm (ζ = 12.01 ± 0.51 mV) and 46.28 ± 2.21 nm (ζ = 15.05 ± 0.39 mV), respectively. Zeta potential, entrapment, in vitro release, and pH-based stability studies were investigated and influence of formulation parameters are discussed. Cell-line-based cytotoxicity assay (A549 and H460 cells) and cell internalization assay (H460 cell line) were performed to assess the influence on the bioperformance of these nanoformulations.
登录
查看更多内容
影响因子：
4.1
作者：
Maheshwari, Rahul G. S.;Tekade, Rakesh K.;Jain, Dinesh K.
通讯作者：
Jain, Dinesh K.
影响因子：
5.8
作者：
Dreis, S.;Rothweller, F.;Langer, K.
通讯作者：
Langer, K.
影响因子：
2.4
作者：
Dhakad, Raghvendra Singh;Tekade, Rakesh Kumar;Jain, Narendra Kumar
通讯作者：
Jain, Narendra Kumar
影响因子：
10.8
作者：
Chung, Yong-Il;Kim, Jong Chul;Kwon, Ick Chan
通讯作者：
Kwon, Ick Chan
影响因子：
--
作者：
Chougule, Mahavir B;Padhi, Bijay K;Misra, Ambikanandan
通讯作者：
Misra, Ambikanandan